Mycosis Fungoides News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides - Oncology Nurse Advisor



Cancer Network
 
Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides 
Oncology Nurse Advisor
The US Food and Drug Administration (FDA) granted regular approval to brentuximab vedotin (Adcetris) for 2 indications: primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF), in adults who have ...
Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis ... Cancer Therapy Advisor
FDA Approves Brentuximab Vedotin for Cutaneous Lymphoma Cancer Network
FDA Approves New Lymphoma Indication for Adcetris Managed Care magazine
The Pharma Letter 
all 6 news articles » 


(Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing ... - Business Wire (press release)



Puget Sound Business Journal (Seattle)
 
(Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing ... 
Business Wire (press release)
?Our phase 3 ALCANZA clinical trial evaluating ADCETRIS in patients with primary cutaneous anaplastic large cell lymphoma and mycosis fungoides, which are the most common types of cutaneous T-cell lymphoma, demonstrated superior efficacy with ...
Adcetris Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma Monthly Prescribing Reference
FDA Approves Brentuximab Vedotin for CTCL OncLive
FDA approves drug developed in Bothell to treat disfiguring blood cancer The Daily Herald
Pharmacy Practice News  -Medscape  -Healio 
all 13 news articles » 


Mycosis Fungoides Research Report: Clinical, Pre-Clinical and ... - Medgadget (blog)



Mycosis Fungoides Research Report: Clinical, Pre-Clinical and ... 
Medgadget (blog)
Mycosis Fungoides-Pipeline Insights, a latest market research report available at The Market Reports provides the most up to date data of this segment cove.

and more » 


Brentuximab Vedotin Nears European Approval for CTCL - OncLive



OncLive
 
Brentuximab Vedotin Nears European Approval for CTCL 
OncLive
ALCANZA included 131 patients with CD30-expressing (?10% of infiltrate by central review) mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL), the 2 most common subtypes of CTCL. The intent-to-treat population ...

 


Cutaneous T-cell Lymphoma Therapy Adcetris Approved by FDA - Lymphoma News Today



Lymphoma News Today
 
Cutaneous T-cell Lymphoma Therapy Adcetris Approved by FDA 
Lymphoma News Today
The FDA has approved Adcetris for the treatment of adults with primary cutaneous anaplastic large cell lymphoma and CD30-expressing mycosis fungoides.
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion ... Nasdaq
Seattle Genetics wins new OK for Adcetris | BioPharma Dive BioPharma Dive

all 3 news articles » 


Trillium Announces Private Placement - Marketwired - Marketwired (press release)



Trillium Announces Private Placement - Marketwired 
Marketwired (press release)
TORONTO, ONTARIO--(Marketwired - Nov. 15, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company ...

and more » 


FDA Approves DVAX's Hep B Vaccine, OMER Catches Eyes, It's 4 For SGEN's Adcetris - Nasdaq



San Francisco Business Times
 
FDA Approves DVAX's Hep B Vaccine, OMER Catches Eyes, It's 4 For SGEN's Adcetris 
Nasdaq
The FDA has approved an expanded indication for Seattle Genetics Inc.'s (SGEN) ADCETRIS for use in the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have ...
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults (NASDAQ:DVAX) Dynavax Technologies Corporation

all 39 news articles » 


FDA approvals granted for brentuximab, letermovir - medwireNews



FDA approvals granted for brentuximab, letermovir 
medwireNews
Brentuximab vedotin may now be used for adults with pcALCL or CD30-expreessing mycosis fungoides who have previously used at least one systemic therapy, at a recommended intravenous dose of 1.8 mg/kg up to 180 mg over 30 minutes. Treatment may ...

 


miRagen Therapeutics' (MGEN) CEO William Marshall on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha



miRagen Therapeutics' (MGEN) CEO William Marshall on Q3 2017 Results - Earnings Call Transcript 
Seeking Alpha
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will ...

 


Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting - Marketwired (press release)



Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting 
Marketwired (press release)
... 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368).

and more »